A couple of months ago, Shoreline Biosciences Chairman and CEO Kleanthis Xanthopoulos, Ph.D. told me that the key to securing venture capital is found in your people. Fresh on the heels of securing a $140 million round of financing, he told me, “More than anything else, it’s about the quality of the people you bring […]

A Florida biotechnology company has now made itself at home in its $55 million Vandalia processing center, pursuing what company leaders believe are advancements in human tissue and nerve repair. “The entire project team is inside the new facility,” Todd Puckett, operations manager for the Axogen Corp. Industrial Park Drive site, said in a recent […]

Aristea Therapeutics was spun out of AstraZeneca to develop medicines for rare, immunologic disorders. Its lead program in development is an experimental therapy for a rare skin condition that causes repeated outbreaks of painful pustules on the hands and feet and is being looked at for other neutrophil-mediated diseases. We spoke to James Mackay, president […]